In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This analysis is based on information available up to January 13, 2025, and reflects the most recent data and analyst perspectives on BioCryst Pharmaceuticals, Inc. Gain an edge in your investment ...

Needham analyst Serge Belanger raised the firm’s price target on BioCryst (BCRX) to $15 from $14 and keeps a Buy rating on the shares. The ...

The press release states that BioCryst Pharmaceuticals anticipates approaching quarterly earnings per share profitability during the latter part of the fiscal year ending December 31, 2025.

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO ...